Shark vNAR Proteins for Immunoprivileged Organ Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions such as sepsis, psoriasis, and angiogenesis-related diseases face limitations in effectively targeting and neutralizing pro-inflammatory cytokines like TNF-alpha and VEGF, particularly in accessing immunoprivileged organs and achieving sustained therapeutic effects with minimal side effects.
Innovation Solution
Development of pharmaceutical compositions containing vNARs derived from shark IgNAR immunoglobulins, specifically designed to bind and neutralize TNF-alpha and VEGF, allowing for topical or systemic administration to reach target tissues, including immunoprivileged organs, with enhanced stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to neutralize cytokines, then therapeutic efficacy is achieved, but the ability to access immunoprivileged organs is limited
Solution Approach 1:
The patent segments the conventional antibody structure into a smaller single-domain variable region (vNAR) derived from shark IgNAR. This segmentation reduces molecular size from typical full antibody dimensions to approximately 15 kDa, enabling penetration into immunoprivileged organs while retaining cytokine-neutralizing functionality.
Solution Approach 2:
The patent extracts only the essential antigen-binding variable domain from the full antibody structure, discarding the constant regions and other domains. This extraction creates a minimalistic vNAR molecule that maintains therapeutic efficacy while achieving improved tissue penetration and access to previously inaccessible sites.
2Ease of operation
If vNARs are used to achieve deep tissue penetration, then access to immunoprivileged organs is improved, but molecular stability may be compromised
Solution Approach 1:
The patent modifies the molecular parameters of the antibody by selecting and engineering vNARs with optimized amino acid sequences that enhance both tissue penetration capability and molecular stability. Specific CDR region configurations and framework adjustments maintain structural integrity while enabling deep tissue access.
Solution Approach 2:
The patent creates composite therapeutic molecules by combining vNAR domains with Fc fusion partners or other stabilizing elements. This composite approach maintains the small size and penetration ability of vNAR while adding stability and half-life extension through fusion with larger protein structures.
3Ease of operation
If smaller antibody fragments are used to improve tissue penetration, then bioavailability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes the natural self-assembly and folding properties of vNAR domains to achieve proper structure without complex manufacturing interventions. The single-domain structure folds autonomously into the correct conformation, simplifying production compared to multi-chain antibodies that require precise assembly of multiple components.
Solution Approach 2:
The patent optimizes expression parameters and purification conditions specifically for vNAR molecules, leveraging their small size and stability characteristics. This includes adjusting pH, temperature, and buffer conditions during manufacturing to maintain vNAR integrity while simplifying downstream processing compared to conventional antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vNARs effectively neutralize TNF-alpha and VEGF, providing therapeutic benefits for conditions like sepsis, psoriasis, and angiogenesis-related diseases by improving tissue penetration and reducing side effects, while maintaining stability and efficacy over time.
Implementation Method 1
specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization
Data Source
AI summary
The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described.